Neutralizing Epitope-Based Growth Enhancing Vaccine

Abstract

The invention provides a fusion protein comprising a plant virus coat protein and a GDF8 peptide domain, or antigenic fragment of the GDF8 peptide domain. Plant virus vectors expressing the fusion protein and methods of using these vectors are also provided.

1 . A fusion protein comprising:
 (a) a GDF8 peptide domain, or an antigenic fragment of the GDF8 peptide domain, wherein the GDF8 peptide domain comprises amino acid residues 327 to 346 of SEQ ID NO:1; and   (b) a plant virus coat protein, or at least one fragment of a plant virus coat protein;   
     
     
         2 . The fusion protein of  claim 1 , wherein the plant virus coat protein is a tobamovirus coat protein. 
     
     
         3 . The fusion protein of  claim 2 , wherein the GDF8 peptide domain or the antigenic fragment of the GDF8 peptide domain is fused to a fragment of the coat protein; and wherein the tobamovirus virus is a tobacco mosaic virus strain U1 or U5. 
     
     
         4 . The fusion protein of  claim 1  comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 54, and SEQ ID NO: 55. 
     
     
         5 . The fusion protein of  claim 1 , wherein the antigenic fragment of the GDF8 peptide domain comprises amino acid residues 329 to 332 of SEQ ID NO: 1. 
     
     
         6 . The fusion protein of  claim 5 , wherein the antigenic fragment of the GDF8 peptide domain comprises amino acid residues 327 to 338 of SEQ ID NO: 1. 
     
     
         7 . The fusion protein of  claim 1   (a) wherein the coat protein is from a single-stranded plus-sense plant RNA virus; and   (b) the GDF8 peptide domain is fused to the coat protein at a position selected from the group consisting of:
 (i) the N-terminus of the coat protein, 
 (ii) the C-terminus of the coat protein, 
 (iii) four amino acids from the C-terminus of the coat protein, and 
 (iv) within an externally exposed loop region of the coat protein, 
   wherein the fusion protein elicits an immune response to GDF8, with or without an adjuvant.   
     
     
         8 . The fusion protein of  claim 1 , wherein the GDF8 peptide domain comprises one or more amino acid substitutions,
 wherein there are no more than five amino acid substitutions between amino acid residues 327 to residue 346 of SEQ ID NO: 1; and   wherein the fusion protein specifically binds to rat monoclonal antibody 788.   
     
     
         9 . The fusion protein of  claim 1  wherein the GDF8 peptide domain comprises amino acid substitutions at a position selected from the group consisting of residues 328, 329, 331, 333, 335 of SEQ ID NO: 1, and any combination(s) thereof. 
     
     
         10 . The fusion protein of  claim 9  wherein,
 (a) amino acid residue 328 is His, Leu, or Asn;   (b) amino acid residue 329 is Gln or Lys;   (c) amino acid residue 331 is Asn or Ser;   (d) amino acid residue 333 is Arg or Lys; and   (e) amino acid residue 335 is Ser, Pro, or Thr.   
     
     
         11 . The fusion protein of  claim 10  comprising no more than one amino acid substitution between residues 327 to residue 346, provided that the fusion protein specifically binds to rat monoclonal antibody 788. 
     
     
         12 . The fusion protein of  claim 1  that comprises a specific neutralization epitope for an anti-GDF8 antibody. 
     
     
         13 . The fusion protein of  claim 12 , wherein the anti-GDF8 antibody is selected from the group consisting of rat anti-GDF8 monoclonal antibody 788 and an IgG fraction of goat anti-GDF8 polyclonal antiserum. 
     
     
         14 . The fusion protein of  claim 1  that elicits an immune response to GDF8 when presented to the immune system of a vertebrate, with or without an adjuvant. 
     
     
         15 . The fusion protein of  claim 14  comprising an antigenic fragment of a GDF8 peptide that comprises about 4 to about 16 consecutive amino acid residues from human GDF8. 
     
     
         16 . A nucleic acid that encodes the fusion protein of  claim 1 . 
     
     
         17 . The nucleic acid of  claim 16  that comprises nucleotide 1112 to nucleotide 1171 of SEQ ID NO: 2. 
     
     
         18 . A replicable vector comprising the nucleic acid of  claim 16 . 
     
     
         19 . The replicable vector of  claim 18  that is a selected from the group consisting of a plasmid, a phage, a cosmid, and a virus. 
     
     
         20 . The replicable vector of  claim 19  that is a tobamo virus. 
     
     
         21 . The replicable vector of  claim 20  that is a tobacco mosaic virus selected from the group consisting of TMV-FV1, TMV-FV2, TMV-FV3, TMV-FV4, TMV-FV5, TMV-FV6 and TMV-FV7. 
     
     
         22 . A host cell comprising the replicable vector of  claim 18 . 
     
     
         23 . The host cell of  claim 22  that is a plant cell. 
     
     
         24 . A tobacco plant that comprises the host cell of  claim 23 . 
     
     
         25 . A method of producing a fusion protein comprising a GDF8 peptide domain or an antigenic fragment of a GDF8 peptide domain comprising the steps of:
 (a) culturing the host cell of  claim 22 ; and   (b) expressing the encoded fusion protein.   
     
     
         26 . The method of  claim 25  further comprising the step of recovering the fusion protein. 
     
     
         27 . A method of producing a fusion protein comprising a GDF8 peptide domain or an antigenic fragment of a GDF8 peptide domain, said method comprising the steps of:
 (a) infecting a tobacco plant with the tobacco mosaic virus of  claim 21 , whereby the tobacco mosaic virus replicates; and   (b) harvesting the replicated tobacco mosaic virus.   
     
     
         28 . The method of  claim 27  further comprising a step of isolating the fusion protein from the harvested plant virus. 
     
     
         29 . A fusion protein produced by the method of  claim 26 . 
     
     
         30 . A fusion protein produced by the method of  claim 27 . 
     
     
         31 . A vaccine composition comprising the fusion protein of  claim 1 . 
     
     
         32 . The vaccine composition of  claim 31  further comprising an adjuvant. 
     
     
         33 . A method of eliciting an anti-GDF8 immune response in an animal, comprising administering to the animal an effective amount of the vaccine composition of  claim 31 . 
     
     
         34 . A method of down-regulating GDF8 activity in an animal comprising immunizing the animal with an effective amount of the vaccine composition of  claim 31 .